Literature DB >> 9155671

Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma.

M V González1, M L Artímez, L Rodrigo, C López-Larrea, M J Menéndez, V Alvarez, R Pérez, M F Fresno, M J Pérez, A Sampedro, E Coto.   

Abstract

AIMS: To study the loss of heterozygosity and the presence of mutations at the p53, p16/CDKN2, and APC genes in Barrett's oesophagus, low grade dysplastic oesophageal epithelium, and adenocarcinoma of the oesophagus; to relate the presence of alterations at these genes with the progression from Barrett's oesophagus to adenocarcinoma.
METHODS: DNA was extracted from paraffin blocks containing tissue from Barrett's oesophagus (12 samples), low grade dysplasia (15 cases), and adenocarcinoma (14 cases). Loss of heterozygosity (LOH) at the p53, p16, and APC genes was determined by comparing the autoradiographic patterns of several microsatellite markers between the normal tissue and the malignant tissue counterpart. SSCP was used to determine the presence of mutations at p53 (exons 5 to 8), p16 (exon 2), and APC. Homozygous deletion of the p16 gene was defined through polymerase chain reaction followed by Southern blot.
RESULTS: LOH at the p53, p16, and APC genes was not observed in Barrett's oesophagus without dysplasia, and increased to 90% (p53), 89% (p16), and 60% (APC) in the adenocarcinomas. The p53 gene was mutated in only two adenocarcinomas (codons 175 and 245). In one case a mutation at the APC gene (codon 1297) was found. No patient had mutation at the second exon of p16. However, this gene was homozygously deleted in three of the 12 adenocarcinomas.
CONCLUSIONS: The tumour suppressor genes p53, p16, and APC are often deleted in adenocarcinomas derived from Barrett's oesophagus. Mutations at these genes are also found in the adenocarcinomas, including the homozygous deletion of the p16 gene. However, the absence of genetic alterations in the Barrett's oesophagus and the low grade dysplastic epithelia suggest that mutations at these genes develop later in the progression from Barrett's oesophagus to adenocarcinoma.

Entities:  

Mesh:

Year:  1997        PMID: 9155671      PMCID: PMC499815          DOI: 10.1136/jcp.50.3.212

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  31 in total

1.  The 1993-94 Généthon human genetic linkage map.

Authors:  G Gyapay; J Morissette; A Vignal; C Dib; C Fizames; P Millasseau; S Marc; G Bernardi; M Lathrop; J Weissenbach
Journal:  Nat Genet       Date:  1994-06       Impact factor: 38.330

2.  The management of high grade dysplasia and early cancer in Barrett's esophagus. A multidisciplinary problem.

Authors:  V W Rusch; D S Levine; R Haggitt; B J Reid
Journal:  Cancer       Date:  1994-08-15       Impact factor: 6.860

3.  Frequent loss of heterozygosity on chromosome 9 in adenocarcinoma and squamous cell carcinoma of the esophagus.

Authors:  L Tarmin; J Yin; X Zhou; H Suzuki; H Y Jiang; M G Rhyu; J M Abraham; M J Krasna; J Cottrell; S J Meltzer
Journal:  Cancer Res       Date:  1994-12-01       Impact factor: 12.701

4.  Genomic DNA and messenger RNA expression alterations of the CDKN2B and CDKN2 genes in esophageal squamous carcinoma cell lines.

Authors:  X Zhou; H Suzuki; Y Shimada; M Imamura; J Yin; H Y Jiang; L Tarmin; J M Abraham; S J Meltzer
Journal:  Genes Chromosomes Cancer       Date:  1995-08       Impact factor: 5.006

5.  p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia.

Authors:  K Neshat; C A Sanchez; P C Galipeau; P L Blount; D S Levine; G Joslyn; B J Reid
Journal:  Gastroenterology       Date:  1994-06       Impact factor: 22.682

6.  Frequency of homozygous deletion at p16/CDKN2 in primary human tumours.

Authors:  P Cairns; T J Polascik; Y Eby; K Tokino; J Califano; A Merlo; L Mao; J Herath; R Jenkins; W Westra; J L Rutter; A Buckler; E Gabrielson; M Tockman; K R Cho; L Hedrick; G S Bova; W Isaacs; W Koch; D Schwab; D Sidransky
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

7.  A cell cycle regulator potentially involved in genesis of many tumor types.

Authors:  A Kamb; N A Gruis; J Weaver-Feldhaus; Q Liu; K Harshman; S V Tavtigian; E Stockert; R S Day; B E Johnson; M H Skolnick
Journal:  Science       Date:  1994-04-15       Impact factor: 47.728

8.  Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma.

Authors:  T Mori; K Miura; T Aoki; T Nishihira; S Mori; Y Nakamura
Journal:  Cancer Res       Date:  1994-07-01       Impact factor: 12.701

9.  Mutations of the APC gene occur during early stages of gastric adenoma development.

Authors:  G Tamura; C Maesawa; Y Suzuki; H Tamada; M Satoh; S Ogasawara; M Kashiwaba; R Satodate
Journal:  Cancer Res       Date:  1994-03-01       Impact factor: 12.701

10.  TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus.

Authors:  R Hamelin; J F Fléjou; F Muzeau; F Potet; P Laurent-Puig; F Fékété; G Thomas
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

View more
  28 in total

1.  Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence.

Authors:  R V Lord; D Salonga; K D Danenberg; J H Peters; T R DeMeester; J M Park; J Johansson; K A Skinner; P Chandrasoma; S R DeMeester; C G Bremner; P I Tsai; P V Danenberg
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

Review 2.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

3.  Parathyroid hormone-related protein production by adenocarcinoma in Barrett's esophagus patient with dermatomyositis.

Authors:  S Tanabe; H Mitomi; M Sada; I Yamazaki; T Akaboshi; I Okayasu; T Kameya; K Saigenji
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

4.  Routine morphometrical analysis can improve reproducibility of dysplasia grade in Barrett's oesophagus surveillance biopsies.

Authors:  J P A Baak; F J W ten Kate; G J A Offerhaus; J J van Lanschot; G A Meijer
Journal:  J Clin Pathol       Date:  2002-12       Impact factor: 3.411

5.  Radiofrequency ablation for dysplasia in Barrett's esophagus restores β-catenin activation within esophageal progenitor cells.

Authors:  K Krishnan; S Komanduri; J Cluley; R Dirisina; P Sinh; Jeff Z Ko; L Li; R B Katzman; T A Barrett
Journal:  Dig Dis Sci       Date:  2011-09-24       Impact factor: 3.199

Review 6.  Risk factors for neoplastic progression in Barrett's esophagus.

Authors:  Elizabeth F Wiseman; Yeng S Ang
Journal:  World J Gastroenterol       Date:  2011-08-28       Impact factor: 5.742

7.  Deletion at fragile sites is a common and early event in Barrett's esophagus.

Authors:  Lisa A Lai; Rumen Kostadinov; Michael T Barrett; Daniel A Peiffer; Dimitry Pokholok; Robert Odze; Carissa A Sanchez; Carlo C Maley; Brian J Reid; Kevin L Gunderson; Peter S Rabinovitch
Journal:  Mol Cancer Res       Date:  2010-07-20       Impact factor: 5.852

8.  Evidence for DNA damage checkpoint activation in barrett esophagus.

Authors:  Urs von Holzen; Tina Chen; Amelie Boquoi; Joel E Richter; Gary W Falk; Andres J Klein-Szanto; Harry Cooper; Sam Litwin; David S Weinberg; Greg H Enders
Journal:  Transl Oncol       Date:  2010-02       Impact factor: 4.243

9.  TP53 gene mutations are rare in nondysplastic Barrett's esophagus.

Authors:  Kamila Novotna; Marie Trkova; Alexandr Pazdro; Milan Smejkal; Alzbeta Soukupova; Daniela Kodetova; Premysl Smejkal; Zdenek Sedlacek
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

10.  Chromosome 3p loss of heterozygosity and mutation analysis of the FHIT and beta-cat genes in squamous cell carcinoma of the head and neck.

Authors:  M V González; M F Pello; P Ablanedo; C Suárez; V Alvarez; E Coto
Journal:  J Clin Pathol       Date:  1998-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.